Neonatal HSV: Difference between revisions
From IDWiki
(Updated Pathophysiology and added Management) |
(→: added Epidemiology) |
||
Line 2: | Line 2: | ||
*See also [[Herpes simplex virus]] |
*See also [[Herpes simplex virus]] |
||
+ | |||
+ | === Epidemiology === |
||
+ | |||
+ | *Risk of transmission is determined by maternal serostatus at time of maternal genital infection |
||
+ | **Newly acquired |
||
+ | ***First-episode primary infection (mother has no serum antibodies to HSV-1 or -2 at onset): risk of transmission is about 60% |
||
+ | ***First-episode nonprimary infection (mother has a new infection with one HSV type in the presence of antibodies to the other type): risk of transmission is less than 40% |
||
+ | **Recurrent (mother has pre-existing antibodies to the HSV type that is isolated from the genital tract): risk of transmission is less than 2% |
||
===Pathophysiology=== |
===Pathophysiology=== |
||
Line 37: | Line 45: | ||
*Usually presents in the first or second week of life |
*Usually presents in the first or second week of life |
||
− | == |
+ | ==Management== |
− | * |
+ | *'''Disseminated disease:''' high-dose [[Is treated with::acyclovir]] 60 mg/kg/day IV divided q8h for at least 21 days |
− | ** |
+ | **If CNS disease, repeat lumbar puncture at the end of therapy to document resolution of CSF parameters and ensure that PCR is negative |
− | * |
+ | *'''Localized CNS disease:''' same as for disseminated |
− | * |
+ | *'''Localized skin, eye, and mouth disease:''' high-dose [[Is treated with::acyclovir]] 60 mg/kg/day IV divided q8h for at least 14 days |
− | ** |
+ | **For eye involvement, consult and ophthalmologist to add topical trifluridine, idoxuridine, or vidarabine |
==Prognosis== |
==Prognosis== |
Revision as of 20:43, 20 July 2020
Background
- See also Herpes simplex virus
Epidemiology
- Risk of transmission is determined by maternal serostatus at time of maternal genital infection
- Newly acquired
- First-episode primary infection (mother has no serum antibodies to HSV-1 or -2 at onset): risk of transmission is about 60%
- First-episode nonprimary infection (mother has a new infection with one HSV type in the presence of antibodies to the other type): risk of transmission is less than 40%
- Recurrent (mother has pre-existing antibodies to the HSV type that is isolated from the genital tract): risk of transmission is less than 2%
- Newly acquired
Pathophysiology
- Generally acquired at time of delivery, though 5-8% may be congenital
- Localized CNS infection is thought to occur by retrograde axonal transmission
Clinical Presentation
- Incubation period 7 to 21 days post-partum, with range from birth to 6 weeks
- Spectrum of disease from cutaneous to disseminated
Disseminated disease
- 25% of cases
- Sepsis syndrome that predominantly affects the liver, lungs, and CNS
- May not have skin findings (25%)
- CNS involved in 60-75%, causing meningoencephalitis
- Can also affect larynx, trachea, esophagus, stomach, lower gastrointestinal tract, spleen, kidneys, pancreas, and heart
- Later in the course of the disease, may develop elevated ALT/AST and direct bilirubin, as well as coagulopathy and thrombocytopenia
- Usually presents in the first or second week of life
- Should be considered in sepsis without bacterial cause and with liver dysfunction or coagulopathy
Localized CNS disease
- 30% of cases
- Usually presents in the second or third week of life
- May not have cutaneous manifestations
- Can cause seizures
Skin, eye, and mouth disease
- 45% of cases
- Localized to skin, eyes, and/or mouth
- Usually presents in the first or second week of life
Management
- Disseminated disease: high-dose acyclovir 60 mg/kg/day IV divided q8h for at least 21 days
- If CNS disease, repeat lumbar puncture at the end of therapy to document resolution of CSF parameters and ensure that PCR is negative
- Localized CNS disease: same as for disseminated
- Localized skin, eye, and mouth disease: high-dose acyclovir 60 mg/kg/day IV divided q8h for at least 14 days
- For eye involvement, consult and ophthalmologist to add topical trifluridine, idoxuridine, or vidarabine
Prognosis
- Disseminated disease has 65% mortality if untreated, improves to 30% with treatment
- With CNS disease, 80% have developmental problems
- Prognosis much better with isolated cutaneous disease